The new AAVX and AAV9 are designed to be used with its Amperia benchtop quantification platform
Life sciences technology company Abselion has launched the AAVX Total Capsid Quantification Kit and the AAV9 Total Capsid Quantification Kit.
Both kits are designed to be used with its Amperia benchtop quantification platform, including Thermo Fisher Scientific's CaptureSelect affinity reagents.
The kits give researchers working in adeno-associated virus (AAV) development and characterisation a more efficient and accessible workflow, aiding in generating reproducible titre measurements across a selection of serotypes and process conditions.
Abselion's Amperia benchtop platform is a solution for rapid and accurate automated quantification of a range of biomolecules, without the need for optics, fluidics, or specialist training.
Each kit, supplied in a read-to-use format, includes sensor strips, assay plates, matched detection reagents, and assay buffers for both the binding and detection steps.
Abselion has entered into a licensing agreement with Thermo Fisher Scientific, incorporating CaptureSelect affinity reagents into its AAV quantification kits.
CaptureSelect technology is created from recombinant single-domain antibodies designed for high target specificity, low cross-reactivity, and consistent batch performance to ensure robust titre quantification.
Both kits utilise a sandwich-style immunoassay format, where biotin- and HRP-conjugated CaptureSelect antibodies are successively applied to bind AAV capsids. Using Amperia sensor strips, the resulting signal is detected electrochemically, allowing accurate quantitative detection over a range of AAV sample types and concentrations.
The AAVX Total Capsid Quantification Kit features CaptureSelect Anti-AAVX Biotin and HRP Conjugates, allowing broad serotype coverage including AAV1–8 and AAVrh10. The AAV9 Total Capsid Quantification Kit includes CaptureSelect Anti-AAV9 Biotin and HRP Conjugates for concentrated quantification of AAV9 particles.
Dr Ruizhi Wang, CEO and founder of Abselion, said: “Reliable quantification of total AAV capsid concentration is key to maintaining consistency and supporting informed decision-making. The integration of Thermo Fisher Scientific’s CaptureSelect reagents strengthens the performance of Abselion’s AAV kits and reflects our focus on making high-quality titre measurement simpler and more accessible. With these additions, Amperia offers researchers a ready-to-use solution that combines trusted reagent technologies with a streamlined assay format, enabling reliable quantification across a wider range of serotypes and development workflows.”
Dr Kelly Flook, senior manager of product management, pharma analytics, and Thermo Fisher Scientific, said: “CaptureSelect affinity reagents are designed to deliver high specificity and lot-to-lot consistency, making them well-suited for applications such as AAV capsid quantification. We’re pleased that Abselion has incorporated these reagents under licence to support their assay kits for the Amperia platform.”
